Phase I Study of S-trans, Trans-farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients with Refractory Hematologic Malignancies

BACKGROUND: RAS/RAF/MAPK activation (mutational or non-mutational) is a key pathway for survival and proliferative advantage of leukemic cells. Salirasib is an oral RAS inhibitor that causes dislocation of RAS by competing directly with farnesylated RAS in binding to its putative membrane binding pr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Lymphoma Myeloma Leuk
Hauptverfasser: Badar, Talha, Cortes, Jorge E, Ravandi, Farhad, O’Brien, Susan, Verstovsek, Srdan, Garcia-Manero, Guillermo, Kantarjian, Hagop, Borthakur, Gautam
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2015
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4509631/
https://ncbi.nlm.nih.gov/pubmed/25795639
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2015.02.018
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge